|
What sets Bristol-Myers Squibb apart?
It is our focus on finding innovative medicines to
combat serious diseases and getting them to
patients faster and more efficiently.
Since 1858, medicines made by Bristol-Myers
Squibb have helped millions of patients around
the world fight serious diseases such as cancer,
heart disease, diabetes, HIV/AIDS, chronic
hepatitis B, rheumatoid arthritis and various
psychiatric disorders.
From those early days, we have been developing
our offering to better meet the needs of patients.
By combining the best elements of a leading-edge
biotech company with the resources of a major
pharmaceutical company, we are transforming into
a new kind of enterprise: a next-generation
BioPharma leader.
At the heart of our BioPharma strategy are the
medicines that give meaningful hope to patients
and physicians and bring value to our shareholders
and customers. Since 2002, we’ve introduced
eight new products for the treatment of numerous
serious diseases.
As well as all these products now on the market,
scores of additional investigational medicines are
advancing through the company’s pharmaceutical
development pipeline. In fact, Bristol-Myers Squibb
is recognised as having one of the most productive
pipelines in the industry.
Over the years, Bristol-Myers Squibb and its
employees have received awards and recognition.
We have been listed as one of the best companies
to work for by The Sunday Times. We have also
been acknowledged as an industry leader in
environment, health and safety management.
Finally, our philanthropic programmes have given
new hope to some of the world’s most vulnerable
citizens.
Key facts
Chairman & CEO - James M Cornelius
General Manager BMS UK - Frédéric Duchesne
UK Headquarters - Uxbridge Business Park, Sanderson Rd,Uxbridge, Middlesex UB8 1DH
Website - www.b-ms.co.uk
Net Sales Worldwide - $20.6 billion (2008)
R&D Investment Worldwide - $3.5 billion (2008)
|
